SubsidieMeestersRevolutionizing Skin Health with our Advanced Engineered Biotherapeutics
The SkinEngineering project aims to advance a patented biotherapeutic technology using genetically engineered skin bacteria for effective acne treatment, targeting regulatory validation and commercialization.
Projectdetails
Introduction
We have developed a ground-breaking patented technology that uses genetically engineered skin bacteria (C. acnes) to deliver biotherapeutics directly to the skin, offering safe, effective, and long-lasting treatment for skin conditions such as acne. Our modified microbes continuously produce and secrete therapeutic molecules in the hair follicle, addressing the problems associated with invasive procedures and the poor transdermal penetration of traditional topical treatments.
Preclinical Results
Preclinical results from our previous EIC Transition project SKINDEV (coordinated by UPF) have demonstrated significant efficacy in reducing sebum and inflammation in vitro. Additionally, further studies have shown successful engraftment and safety in mouse models.
Project Goals
The SkinEngineering project will advance our technology from proof-of-concept (TRL3) to preclinical and regulatory validation (TRL5), bridging the gap between promising research outcomes and the stage where we are ready to enter into commercial agreements with potential partners.
Refinement and Safety
SkinEngineering will help us further refine our platform, complete preclinical studies, and address regulatory and manufacturing aspects. We will also focus on ensuring the safety of our engineered bacteria, including robust biocontainment strategies.
Market Validation
We have preliminarily validated the market fit of this effective and non-invasive therapy without adverse effects, confirming that it meets the needs of clinicians and patients in the €14 billion acne market. Our biotherapeutic also reduces the need for antimicrobial-based treatments, helping combat antimicrobial resistance, a key public health issue.
Commercialization Pathway
Our commercialization pathway involves launching a spin-off, Synflora, with SkinEngineering refining our business model and go-to-market strategy. Successful project outcomes will capture the attention of key stakeholders, e.g., investors, pharma/cosmetic companies, and end users, boosting our company’s awareness and enhancing its investment readiness.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-5-2025 |
| Einddatum | 30-4-2028 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSIDAD POMPEU FABRApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SKIN MICROBIAL DEVICESSKINDEV aims to develop Smart Skin Microbial Devices for non-invasive monitoring and treatment of atopic dermatitis through innovative sensing technologies and genetic engineering. | EIC Pathfinder | € 1.718.408 | 2023 | Details |
Microbiome-based diagnostics and therapeuticsThis project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression. | ERC POC | € 150.000 | 2023 | Details |
ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic DiseasesISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration. | EIC Pathfinder | € 2.433.300 | 2023 | Details |
Development of a non-invasive medical device to measure the skin biomechanical properties: assessment of the commercial feasibilityAssesSkin aims to develop a non-invasive medical device for assessing skin biomechanical properties, enhancing personalized treatment in dermatology and cosmetics while addressing regulatory pathways. | ERC POC | € 150.000 | 2024 | Details |
SKIN MICROBIAL DEVICES
SKINDEV aims to develop Smart Skin Microbial Devices for non-invasive monitoring and treatment of atopic dermatitis through innovative sensing technologies and genetic engineering.
Microbiome-based diagnostics and therapeutics
This project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression.
ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
ISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration.
Development of a non-invasive medical device to measure the skin biomechanical properties: assessment of the commercial feasibility
AssesSkin aims to develop a non-invasive medical device for assessing skin biomechanical properties, enhancing personalized treatment in dermatology and cosmetics while addressing regulatory pathways.